class = “cf”>
Stressing that the genetic vaccines developed by German biotech company BioNTech and American Moderna do not rely solely on antibodies to create immunity, the researchers said that immune responses stimulated at the cellular level offer longer-term protection against disease.
The researchers concluded that such vaccines may offer protection against disease even though the level of antibodies in the body naturally decreases over time, so it may not be necessary to be revaccinated every year or to supplement with a dose. immune booster.
Ali Ellebedy, an immunologist from the University of Washington, said that in studies conducted, it was observed that even in patients with mild Kovid-19, plasma cells in the blood continued to produce antibodies for a long time by attaching to in the bone. marrow after healing.
Expressing that they expect similar blood cell formation to occur in those who are vaccinated, Ellebedy noted that on the other hand, B cells, which confer immunity at the cellular level, may intervene to produce new antibodies even after the level of antibodies in the body decreases.
Ellebedy pointed out that if B cells fail, immune T cells will step in and fight off infected cells.
Noting that even the viruses that cause the common cold can make people sick again for 2 to 5 years, Ellebedy said, “Our natural immunity can wane over time. But we don’t know what will happen with the vaccine. We can produce a more successful result with mRNA vaccines than with nature and natural infection. ”Makes his assessment.
Recalling that the vaccination against Kovid-19 has just started, scientists said that ongoing research must be completed in order to reach definitive conclusions.
MRNA AŞILARI: BİONTECH VE MODERNA
Turkish scientist Prof. Dr. The Kovid-19 vaccine developed by the German biotechnology company BioNTech, of which Uğur Şahin is a founding partner, with the support of the American pharmaceutical company Pfizer, and the vaccine developed by the American biotechnology company Moderna with the support of the The US National Institute of Allergy and Infectious Diseases (NIAID), are widely used in the United States and Europe, and is applied in widespread vaccination campaigns in many countries around the world.
Both vaccines contain messenger ribonucleic acid (mRNA) in their formula. The vaccine developed by BioNTech / Pfizer, thanks to the RNA composition of its formula, activates glycemic enzymes and immunoglobulin G antibodies binding to receptors that neutralize Kovid-19, confers immunity at the cellular level.
It aims to increase the CD4 and CD8 glycoproteins that create the response.
The vaccine candidate, named “mRNA-1273” by Moderna, aims to provide immunity in the body by suppressing the enzyme called “nail protein”, which allows the virus to attach to human cells. It aims to activate the body’s cellular defenses by artificially producing the Kovid-19 nail protein with the messenger RNA in the vaccine formula.
BioNTech / Pfizer vaccine became ‘the first COVID-19 vaccine to be registered in the world’, with UK Medicines and Health Products Regulatory Agency (MHRA) approval for widespread use on December 2 2020. Moderna’s vaccine was first approved for emergency use by the United States Food and Drug Administration (FDA) on December 19, 2020.
Both RNA vaccines have shown high efficacy in clinical trials. After the third phase clinical trials in which thousands of subjects participated, the BioNTech vaccine was reported to be 95% effective in preventing symptomatic cases and the Moderna vaccine to be 94.1% effective.
Bigpara for cryptocurrency markets
Bigpara for cryptocurrency markets